DexTech's OsteoDex meets primary and secondary goals in Phase I/IIa multiple myeloma trial
Bitget2026/10/29 10:53- DexTech Medical finalized the clinical report for its Phase I/IIa OsteoDex trial in relapsed or treatment-resistant multiple myeloma in October 2026.
- The report confirmed previously disclosed positive results, with the trial meeting its primary and secondary objectives.
- No serious treatment-related adverse events occurred; all patients achieved stable disease during treatment.
- Most patients maintained stable disease following treatment completion in February 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Elon Musk: SpaceX (SPCX.US) Q4 revenue is expected to increase by approximately 70% quarter-on-quarter, with government contract income share falling below 10%
Elon Musk stated on Friday that SpaceX (SPCX.US) will continue to reduce its dependence on U.S. government procurement contracts.
After the sharp decline in tech stocks, the White House suddenly canceled the top tech advisor meeting the following day.
The White House has canceled the previously scheduled President’s Council of Advisors on Science and Technology meeting, which was set for Friday and includes prominent tech leaders such as Nvidia CEO Jensen Huang and Meta CEO Mark Zuckerberg. The Department of Energy's meeting page briefly listed November 13 as the new meeting date, but the agency later sent an email retracting this information. Currently, the specific date for rescheduling the meeting remains unclear.
Turtle Creek Asset Management Reports Sale of $347,850 in Jeld-Wen Common Shares
Crypto prices
More
